Restarting Mounjaro After 6 Weeks: What You Need to Get Right

The misconception: picking up at your previous dose after six weeks is fine

The most common assumption people make when restarting Mounjaro is that the dose they were on before they stopped is the dose they return to. It feels logical, you were tolerating 7.5mg or 10mg well, so why not continue there?

The problem is that tirzepatide's effects on gastric emptying and appetite regulation are not simply paused during a break. After six weeks without the medicine, your gut has readjusted. The receptors that tirzepatide activates (both GIP and GLP-1 pathways) respond as if the medicine is largely new again. Restarting at a higher dose means hitting a system that hasn't been gradually prepared, and the result is often significant nausea, vomiting, or diarrhoea that could have been avoided.

Six weeks is the threshold that most clinical guidance treats as requiring a dose reduction on restart. If your gap was shorter (say, two weeks or three weeks) the picture is different, and your prescriber may take a different view. But at six weeks, the safe default is to treat this as a fresh start through the lower doses.

It's also worth being honest about why six weeks passed. A planned break is different from one caused by side effects, illness, or supply issues. Your prescriber needs that context to advise you properly.

What actually happens to your weight and appetite during six weeks off

One thing that surprises people is how quickly appetite returns after stopping Mounjaro. For many, it comes back sharply within one to two weeks, because the medicine's appetite-suppressing effect disappears as it clears the body. Six weeks off is long enough that most of the metabolic changes driven by tirzepatide will have unwound to a significant degree.

Weight regain is common during breaks. This isn't a reflection of willpower; it reflects the biology that these medicines are designed to address. The science behind tirzepatide involves actively dampening hunger signals that are otherwise powerful and persistent. Remove the medicine and those signals return.

This is also why restarting matters: the clinical trial evidence that informed NICE's recommendation of tirzepatide (published as NICE technology appraisal TA1026) was built on continuous use over 72 weeks, not interrupted courses. Any weight regained during a break is not necessarily lost progress, but it does underline that sustained treatment, where clinically appropriate, tends to deliver better outcomes than stop-start use.

If you're weighing up whether Mounjaro makes sense for a longer period, the page on using Mounjaro for just one month covers what a short course can and can't realistically achieve.

The clinical restart process: what your prescriber will look at

Restarting after six weeks is not simply a case of placing a repeat order. A prescriber reviewing a restart will typically want to know: why did you stop, what happened to your weight during the break, have any health conditions changed, and are you on any new medicines that might interact?

The NHS patient-level guidance for tirzepatide, published on the NHS medicines page for tirzepatide, is clear that dose changes and restarts should always be guided by the prescriber. There is no self-managed restart protocol.

In practice, most people restarting after a six-week gap will begin at 2.5mg (the initial tolerability dose) and titrate again from there, typically in four-week steps. Yes, that means several weeks before reaching the therapeutic doses where the bulk of weight loss tends to occur. It's slower, but it's considerably more comfortable than forcing the body to adapt too fast.

One small practical detail: if you keep your pen in the fridge door next to the milk, double-check the storage instructions in your Patient Information Leaflet when you collect your new prescription, the exact room-temperature window for a pen once removed from the fridge is set out there, and it's worth re-reading after a gap.

Our clinical team, including our lead prescriber, reviews every restart request individually. If your circumstances have changed, that's exactly the conversation a clinical review is for.

Cost, continuity, and making a restart decision

A six-week break sometimes happens because of cost. Mounjaro is a private prescription medicine in most cases, and the price has shifted since Eli Lilly revised UK list pricing in September 2025, typical private costs now range roughly £149 to £375 per month depending on dose and provider, as widely reported at the time. If that's been a factor, it's worth reading through the Mounjaro cost page for an honest picture of what private treatment involves and what should be included in any legitimate price.

If the break was unplanned (supply issues, travel, illness) and you're clear on wanting to continue, a restart is entirely reasonable. The process just needs to go through proper clinical channels. For a fuller overview of everything involved in restarting Mounjaro regardless of how long you've been off it, that page covers the wider picture.

Shorter gaps, such as restarting after four weeks or after a month, involve slightly different considerations, your prescriber will apply the same individual assessment, but the tolerance question may land differently. The general Mounjaro overview is a useful reference if you want to revisit how the medicine works before your consultation.

If you're ready to restart and want a same-day clinical review by a GPhC-registered prescriber, start your free consultation and our team will take it from there.